FindTrial
Sign In

ChAdOx1 nCoV-19

BIOLOGICAL5 trials

Sponsors

University of Oxford, EuBiologics Co.,Ltd

Conditions

COVID-19Coronavirus

Phase 1

A Study of a Candidate COVID-19 Vaccine (COV001)
CompletedNCT04324606
University of OxfordCoronavirus
Start: 2020-04-23End: 2025-02-05Updated: 2025-09-03
COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection
NCT04444674
University of OxfordCoronavirus
Start: 2020-06-24End: 2021-12-31Updated: 2020-11-27
A Study of Intranasal ChAdOx1 nCOV-19
CompletedNCT04816019
University of OxfordCoronavirus
Start: 2021-04-01End: 2022-09-30Updated: 2022-10-24

Phase 3

A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults
CompletedNCT05572879
EuBiologics Co.,LtdCOVID-19
Start: 2022-10-01End: 2024-02-09Updated: 2024-06-17
A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older
CompletedNCT05603052
EuBiologics Co.,LtdCOVID-19
Start: 2022-07-11End: 2024-01-15Updated: 2025-01-07

Related Papers

Year-Long Antibody Response to the EuCorVac-19 SARS-CoV-2 Vaccine in Healthy Filipinos
Vaccines2025-07-221 citations
SARS-CoV-2 vaccines elicit differential Fc effector functions
iScience2025-07-15
Interim safety and immunogenicity analysis of the EuCorVac‐19 COVID‐19 vaccine in a Phase 3 randomized, observer‐blind, immunobridging trial in the Philippines
Journal of Medical Virology2024-09-0112 citations
Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease
Nature Communications2024-04-2223 citations
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
2023-11-1548 citations
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)
Vaccine2023-04-276 citations
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
2022-12-0532 citations
Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine
BMC Medicine2022-11-3033 citations
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
2022-10-2023 citations
Comparison of blood and lymph node cells after intramuscular injection with HIV envelope immunogens
Frontiers in Immunology2022-10-0515 citations
CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study
BMJ Open2021-12-0110 citations
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
2021-09-01208 citations
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
2021-08-17122 citations
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
Nature Communications2021-07-3057 citations
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
New England Journal of Medicine2021-03-161302 citations
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
2021-02-19903 citations
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
2020-12-17264 citations
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
2020-12-083647 citations
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
2020-07-201868 citations
Are Genetic Vaccines the Right Weapon against COVID-19?
Molecular Therapy2020-06-0921 citations